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Abstract 
Growing evidence for glutamate abnormalities in schizophrenia support the development of novel 
antipsychotic agents targeting this system. Early studies investigating modulation of the glutamate 
system using glycine, D-serine and sarcosine in patients with schizophrenia have demonstrated 
significant effects, particularly on negative symptoms, conventionally thought to be refractory to 
antipsychotic drug treatment. Drugs targeting the glutamate system also have a completely different 
side-effect profile to dopamine D2 antagonists, with no propensity to extrapyramidal side-effects, 
prolactinaemia or weight gain. It has been hypothesised that glutamatergic drugs may be of benefit 
to the 20-30% of individuals with schizophrenia who fail to show any response to dopaminergic 
agents, and may be particularly useful in the early stages of the illness, where they may be disease-
modifying. A number of glutamatergic compounds have been  reported as having promising results 
in phase 2 drug trials. If these reach the clinic, they will represent the first truly novel approach to 
pharmacotherapy in schizophrenia for more than 50 years. 
Introduction 
For more than 50 years, the only effective antipsychotic drugs available have been dopamine D2 
receptor antagonists {{948 Kapur,S. 2003;}}, with their clinical potency directly corresponding to their 
affinity at D2 receptors {{137 Seeman,P. 1975;}}. Despite leading to at least a partial clinical response 
in around 2/3 patients with schizophrenia, 1/3 patients will fail to respond to D2 antagonists {{818 
Stone,J.M. 2010;}}. Furthermore, although positive symptoms generally show a reasonable response 
to these drugs, there frequently remain a core of negative symptoms that are refractory to 
antipsychotic treatment {{230 Buchanan,R.W. 1998;232 Tamminga,C.A. 1998;231 Javitt,D.C. 2001;}}. 
 
All currently available antipsychotic drugs have significant, and sometimes potentially life-
threatening, side-effects, which may lead to discontinuation of the treatment. Although the second 
generation of antipsychotic drugs have a lower incidence of extrapyramidal side effects, they are 
associated with other debilitating effects such as impaired glucose tolerance and weight gain, which 
can have significant health consequences.  Thus, there has been a great deal of interest in developing 
new targets for pharmacological treatment in schizophrenia – drugs which might have fewer side 
effects and/or lead to response in patients who do not respond fully to currently available drugs 
{{818 Stone,J.M. 2010;}}. So far, the only major advance in drug treatments for schizophrenia has 
been the discovery of clozapine, which has been consistently shown to have superior efficacy in 
patients unresponsive to other antipsychotic drugs {{139 Kane,J. 1988; 930 McEvoy,J.P. 2006;}}. No 
other agent developed since clozapine has shown  equivalent efficacy, and improvements over first 
generation antipsychotic drugs have been incremental at best. Part of the reason for this lack of rapid 
progress may be due to the fact that drug development in schizophrenia has primarily focused on the 
strategy of developing new drugs that act on the dopamine system rather than developing 
compounds for other targets. 
 Glutamatergic neurotransmission 
Glutamate is the main excitatory neurotransmitter in the brain. Between 60 and 80 percent of total 
brain metabolic activity in the non-stimulated cerebral cortex is utilised by glutamatergic neurones, 
with the remainder being used by GABAergic neurones and glial cells. The synaptic release of 
glutamate and recycling to glutamine in astrocytes is a major metabolic pathway (figure 1), and 
accounts for between 80 and 100 percent of total glutamate trafficking, and it is now accepted that 
no meaningful  distinction can be made between metabolic and neurotransmitter glutamate {{370 
Rothman,D.L. 2003;}}. 
 
Glutamate acts at two main subtypes of neuroreceptor, the metabotropic glutamate receptors and 
the ionotropic glutamate receptors. Metabotropic glutamate receptors (mGluR) are composed of 
three groups (group I-III) distinguished by their sequence homology, pharmacology and second 
messenger systems. Group I receptors (mGluR1 and mGluR5) are predominantly postsynaptic in 
somatodendritic domains and couple via G q/G11 to phospholipase C, whereas group II (mGluR2 and 
mGluR3) and III (mGluR4, mGluR6, mGluR7 and mGluR8) are coupled via  G i/G0 to inhibition of 
adenylate cyclase activity and are primarily presynaptic in axonal domains and terminals, where they 
modulate neurotransmitter release {{886 Kew,J.N. 2005;}}. 
 
Ionotropic glutamate receptors are also divided into three groups, named after the agonists originally 
found to selectively activate them: -amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA), 
kainate and N-methyl- D-aspartate (NMDA) receptors. The ionotropic glutamate receptors are all 
heteromeric ion channels, composed of multiple protein subunits. When activated they lead to an 
increase in cation conductance with differential permeability to Na + and Ca2+ depending upon 
receptor type and subunit composition. NMDA receptors in the adult brain generally show increased 
Ca2+ conductance on activation, whereas kainate receptors lead to an increase in Na + conductance. 
AMPA receptors expressed on GABAergic hippocampal and amygdala interneurons appear to lack an 
edited GluR2 subunit, and show preferential Ca2+ conductance, whereas those on pyramidal neurons 
are non-Ca2+ permeable {{886 Kew,J.N. 2005;415 Dingledine,R. 1999;}}. 
 
NMDA receptor structure and function 
The NMDA receptor is a heteromeric ion channel, formed from a number of subunits (NR1, NR2A-D, 
NR3A-B). NR1 and NR2(A-D) subunits are obligatory for a functional NMDA receptor, and contain 
binding sites for glycine (glycineB site) and glutamate respectively. NR2 subunits show distinct 
regional and developmental distribution, with NR2A and NR2B being expressed primarily in the 
forebrain, NR2C in cerebellar granule cells and NR2D being expressed during f oetal development in 
the midbrain and diencephalon. NR3 subunits require both NR1 and NR2 subunits to form functional 
NMDA receptors. NR3A receptors are expressed primarily during development, and NR3B are only 
found in somatic neurons in brainstem and spinal chord. Activation of the NMDA receptor requires 
two obligatory co-agonists, binding at the glycine and glutamate sites. Two independent glycine, and 
two independent glutamate binding sites appear to be required. Therefore, it has been suggested, 
the minimum requirement for a functional NMDA receptor is two NR1 and two NR2(A-D) subunits 
{{886 Kew,J.N. 2005;}}. At resting potential, NMDA receptors are blocked by extracellular Mg 2+, 
which binds to an intrachannel site of the NMDA receptor complex. In order to allow Ca2+ to enter 
the cell, in addition to glutamate and glycine binding, the cell must depolarise, removing the Mg 2+ 
block {{415 Dingledine,R. 1999;}} (see figure 2).  Uncompetitive allosteric antagonists of the NMDA 
receptor such as ketamine, phencyclidine (PCP) and dizoilpine (MK-801) bind to the inside of the 
NMDA receptor ion channel when it is in its open state, and prevent Ca2+ influx. 
 Glutamate and schizophrenia 
There is growing evidence that changes in glutamatergic neurotransmission may occur in 
schizophrenia, and it has been hypothesized that glutamatergic changes may precede, or give rise to, 
alterations in other downstream neurotransmitter systems such as dopamine {{317 Stone,J.M. 
2007;}}. The glutamate hypothesis of schizophrenia was founded on a number of observations. Drugs 
that act as uncompetitive antagonists at NMDA receptors such as phencyclidine (PCP) and ketamine 
reliably and instantly induce a drug-induced state that closely resembles the symptoms of 
schizophrenia, including thought disorder, odd ideas and delusions , cognitive impairment, and, most 
notably, an emotional withdrawal that has been likened to the negative symptoms of schizophrenia 
{{142 Krystal,J.H. 1994; 820 Morgan,C.J. 2006; 687 Javitt,D.C. 2007;}}. In contrast, drugs that increase 
brain dopamine transmission, such as amphetamine, do not induce cognitive or negative symptoms 
{{158 Krystal,J.H. 2005;}}. Blockade of NMDA receptors by ketamine has been shown to be most 
closely related to negative, rather than positive symptoms {{372 Stone,J.M. 2008;}}, suggesting that 
dopamine and glutamatergic changes may give rise to different symptoms of the illness {{158 
Krystal,J.H. 2005; 372 Stone,J.M. 2008;}}.Secondly, candidate risk genes for schizophrenia are not 
related to the dopamine system, but rather converge on molecules involved in glutamatergic 
neurotransmission {{118 Harrison,P.J. 2005;}}. 
 
These findings suggest, as previously hypothesised, that negative and cognitive symptoms may be at 
the core of schizophrenia {{204 Andreasen,N.C. 1999;}}. Cognitive symptoms have been found to be 
closely associated with negative symptoms in patients with schizophrenia {{932 Addington,J. 
1991;931 Ventura,J. 2009;}}, and negative symptoms are most closely associated with functional 
outcome {{931 Ventura,J. 2009;}}. Early and subtle cognitive decline is one of the first (usually 
undetected) symptoms of schizophrenia {{175 Bilder,R.M. 2006;}}, and it is interesting to speculate 
that these changes might arise secondary to abnormalities in NMDA receptor function or 
glutamatergic transmission. 
 
Studies of the effect of NMDA receptor antagonists on brain structure and function are supportive of 
the hypothesis of abnormalities of glutamatergic transmission in schizophrenia. Seminal work by 
Olney and Farber showed that exposure of rats to systemic injections of NMDA receptor antagonists 
led to neurotoxic changes in cortical brain regions, which they suggested closely resembled the 
reductions in grey matter volume seen in patients with schizophrenia {{78 Olney,J.W. 1995;}}. They 
showed that antagonists for the AMPA subtype of glutamate receptor blocked this toxicity, and 
hypothesised that the cortical toxicity was caused, somewhat counter-intuitively, by excess cortical 
glutamate release. They put forward the theory that NMDA receptors expressed on GABAergic 
interneurons were particularly sensitive to NMDA receptor antagonists and that the resultant 
reduction in inhibitory tone led to disinhibition of glutamatergic projection neurons leading to 
glutamate release and excitotoxicity {{78 Olney,J.W. 1995;}} (figure 3). 
 
This hypothesis was supported by later microdialysis studies showing increased glutamate in 
prefrontal cortex following systemic administration of ketamine {{98 Moghaddam,B. 1997;107 
Lorrain,D.S. 2003;}}. Interestingly, injection of the NMDA receptor antagonist MK-801 into cortical 
regions did not lead to any evidence of neurodegenerative changes, whereas injection into anterior 
thalamus led to the same cortical changes as seen with systemic administration {{174 Sharp,F.R. 
2001;}}, suggesting that thalamus might be a primary site of NMDA receptor blockade in the 
generation of downstream effects by NMDA receptor antagonists, and, by extension, may also be a 
site of NMDA receptor dysfunction in schizophrenia {{77 Olney,J.W. 1999;317 Stone,J.M. 2007;}}. 
 Studies of patients with schizophrenia and first episode psychosis, and in individuals with prodromal 
symptoms of schizophrenia (“at risk mental state” - ARMS), who are at high risk of developing 
schizophrenia {{322 Phillips,L.J. 2000;}}, have generally been supportive of the hypothesis of NMDA 
receptor dysfunction and altered glutamate transmission in the illness {{821 Stone,J.M. 2009;}}. A 
study using a single photon emission tomography (SPET) ligand for the NMDA receptor revealed that 
individuals with schizophrenia who were not currently medicated had lower NMDA receptor binding 
in the left hippocampus compared to healthy volunteers {{188 Pilowsky,L.S. 2006;}} (figure 4). This 
finding was in close agreement to an earlier post-mortem study of mRNA of the NMDA receptor 
subunit NMDAR1, which revealed that patients with schizophrenia showed reduced levels in left 
dentate gyrus {{116 Law,A.J. 2001;}}. Furthermore, in patients treated with typical antipsychotic 
drugs, levels of NMDA receptor binding in the left hippocampus were inversely correlated with 
negative symptoms {{188 Pilowsky,L.S. 2006;}}. 
 
Studies employing Proton Magnetic Resonance Spectroscopy (1H-MRS) have measured cortical 
glutamate and glutamine levels in individuals at high risk of psychosis, as well as patients with first 
episode psychosis and chronic schizophrenia. Glutamine is produced in astrocytes following synaptic 
release of glutamate, and so has been suggested to be a marker of glutamatergic transmission. 
Studies in individuals at risk of psychosis, and patients with first-episode psychosis have found 
evidence of increased glutamatergic transmission in anterior cingulate and frontal cortex {{660 
Stone,J.M. 2009;643 Théberge,Jean 2002;103 Tibbo,P. 2004;542 Bartha,Robert 1997;}}. In contrast, 
studies of patients with chronic schizophrenia have generally found normal or reduced cortical 
glutamate levels {{638 Tayoshi,ShinYa 2009;642 Théberge,Jean 2003;379 Ohrmann,P. 2005;601 
Lutkenhoff,E.S. 2008;905 Rowland,L.M. 2009;906 Block,W. 2000;907 Kegeles,L.S. 2000;908 Ongur,D. 
2009;}}. 
 Subcortical measures of glutamate are less consistent. Individuals at risk of psychosis have been 
shown to have reduced thalamic glutamate levels {{821 Stone,J.M. 2009;}}, whereas patients with 
first-episode and chronic schizophrenia have been reported to have increased thalamic glutamine 
{{642 Théberge,Jean 2003;643 Théberge,Jean 2002;}}. The reason for this discrepancy is not clear, 
but it may represent differences in imaging methodology, or possibly differences in illness subtype as 
increases in cortical glutamate release could be driven by reduced subcortical glutamatergic 
transmission on GABA interneurons or by dysfunctional NMDA receptors expressed on the same 
population of neurons{{78 Olney,J.W. 1995;}}. 
 
There has been much speculation about how glutamate and dopamine may be related in 
schizophrenia, and whether glutamate or dopamine might be more “upstream” in the illness. Olney 
and Farber hypothesised that glutamatergic changes might be related to a primary dopaminergic 
abnormality {{78 Olney,J.W. 1995;}}, whereas others have suggested that abnormalities in glutamate 
transmission or NMDA receptor function could drive changes  in dopamine {{822 Coyle,J.T. 2006;118 
Harrison,P.J. 2005;317 Stone,J.M. 2007;}}. A plausible animal model of schizophrenia suggests that 
increased glutamate efferents from hippocampus may drive increased dopamine neuron responsivity 
{{690 Lodge,D.J. 2006;}}(figure 5). In support of this hypothesis, lower levels of hippocampal 
glutamate (potentially driving increased hippocampal outputs through reduced stimulation of GABA 
interneurons) are associated with increased striatal [18F]DOPA uptake (a marker of presynaptic 
dopamine function) in individuals with an ARMS but not in healthy volunteers {{798 Stone,J.M. 
2010;}}. The fact that this relationship was found in individuals with an ARMS and not in healthy 
volunteers suggests GABA intereneurons in ARMS subjects may be more sensitive to presynaptic 
glutamate levels – possibly due to lower hippocampal NMDA receptor expression {{188 Pilowsky,L.S. 
2006;}} (figure 5).  Drugs targeting glutamatergic transmission might help to normalise these deficits 
and have additional downstream effects on normalising dopamine neuron activity. 
 
Drugs targeting glutamate abnormalities in schizophrenia – studies in patients 
A number of different potential targets have been suggested to reverse the hypothesised 
abnormality of glutamatergic transmission in schizophrenia {{821 Stone,J.M. 2009;}} - see figure 6. 
These include enhancement of the function of NMDA receptors expressed on GABAergic 
interneurons – by increasing synaptic glycine levels, through direct action at the glycineB site, or by 
mGlu5 receptor agonism; enhancement of GABAergic interneuron function (through agonism of Trk1 
receptors, alpha-7 nicotinic receptors or M1 receptors); enhancement of GABA tone on 
glutamatergic projection neurons (through drugs with preferential effects at alpha-2 containing 
GABA receptors); and reduction of the effect of excess downstream glutamate release by antagonism 
of AMPA glutamate receptors, or by reducing glutamate release through agonism of mGlu2/3 
autoreceptors (figure 6). 
Enhancement of NMDA receptor function 
Several studies have investigated the effect of drugs which increase NMDA receptor function via the 
NMDA receptor glycine site: either increasing synaptic glycine levels by inhibiting type 1 glycine 
transporters (GlyT1) and preventing reuptake of synaptic glycine  (sarcosine), or by acting as agonists 
at the glycineB modulatory site (glycine and D-serine). As these compounds were not developed as 
CNS agents, relatively high doses are required for a clinical response (30-60g glycine per day has 
commonly been used). Nonetheless, a number of studies have employed these agents as adjunctive 
treatments in patients with schizophrenia. These have recently been reviewed in a meta-analysis, 
which showed a modest effect on both positive and negative psychotic symptoms {{519 Tsai,G.E. 
2009;}}. No trials of glycineB agonists as monotherapy have been published to date, and it is possible 
that the effect size would be more marked when used as first line treatment. A single study of 
sarcosine as monotherapy showed efficacy, but patients were randomised to low (1g) or high (2g) 
dose sarcosine and so a direct comparison against dopaminergic agents has not yet been made {{840 
Lane,H.Y. 2008;}}. It is interesting to note that glycine, D-serine and sarcosine did not have any 
additional effect when added to clozapine {{519 Tsai,G.E. 2009;}}, possibly because part of the 
superior efficacy of clozapine may be due to intrinsic agonist action at the glycineB modulatory site 
{{837 Schwieler,L. 2008;}}. It must be noted that other currently available antipsychotic drugs 
(including haloperidol, thioridazine, chlorpromazine and clozapine) appear to interact with GlyT1 as 
non-competitive antagonists at therapeutic doses. 
 
Reduction of downstream glutamate release and its effects 
Drugs enhancing the function of alpha-2 subunit containing GABA-A receptors should, theoretically 
lead to reduced downstream glutamate release (figure 6) {{227 Lewis,D.A. 2005;}}. One study of MK-
0777, a benzodiazepine-like drug with selectivity as a partial agonist at alpha-2 and alpha-3 GABA-A 
receptor subunits reported improved cognition in patients with schizophrenia, but no effect on 
psychotic symptoms {{880 Lewis,D.A. 2008;}}. 
 
Lamotrigine, a drug which  inibits glutamate release, has been investigated as an adjunctive 
treatment in schizophrenia. Lamotrigine has been shown to reverse positive, negative and cognitive 
symptoms associated with ketamine administration in healthy volunteers {{216 Hosak,L. 2002;}}, and 
to reverse ketamine-associated changes in brain function measured using fMRI {{665 Deakin,J.F. 
2008;}}. A recent meta-analysis suggests that lamotrigine, in contrast to drugs acting through glycine 
enhancement of NMDA receptor function, is effective as an add-on medication for patients who are 
only partially responsive to clozapine, although effects were relatively modest {{838 Tiihonen,J. 
2009;}}. 
 
Glutamate mGlu 2/3 receptors are presynaptic autoreceptors {{886 Kew,J.N. 2005;}}. Agonists inhibit 
synaptic glutamate release (figure 6), and have been shown to reduce the effects of NMDA receptor 
antagonists, and amphetamine in both animal and human studies  {{384 Moghaddam,B. 2004;386 
Javitt,D.C. 2004;}}.  A recent phase 2 trial of an mGlu2/3 receptor agonist (LY2140023 – an oral 
prodrug of LY404039), in a sample of patients with chronic schizophrenia, reported significant 
improvement in positive and negative symptoms compared to placebo {{354 Patil,S.T. 2007;}}. 
Olanzapine (15 mg daily) was used as an active control group in this study, and although not planned, 
a post-hoc comparison of olanzapine vs. LY2140023 revealed no statistically significant difference in 
terms of response to positive and negative symptoms. LY2140023 showed no propensity to elevated 
prolactin, weight gain or extrapyramidal side-effects, however. It's main reported side effects were 
affective lability (although this was reported to be beneficial in some patients who had severe 
affective flattening leading to increased emotional reponse and spontaneous emotional 
fluctuations), and a mild reduction in body weight and body mass index. One curious feature of the 
study was that the group of patients on placebo showed no improvement during the trial duration – 
whereas it is usual for improvement in symptomatology to be seen in patients in clinical trials on 
both placebo and active drug. A subsequent phase II trial of LY2140023 was reported by Lilly to be 
“inconclusive” due to a large placebo response – with neither LY2140023 nor olanzapine showing a 
significant improvement over placebo. They also reported that convulsions occurred in 3 out of the 
669 patients recruited {{933 Kinon, Bruce J. 2010;}}. The study has not been published in full, and it is 
not clear whether Lilly plan to pursue further trials using this prodrug. 
 
It has been suggested that mGlu2/3 agonists may work primarily through dopaminergic mechanisms 
{{909 Seeman,P. 2009;}}. However, recent work reveals that the efficacy of mGlu2/3 agonists to block 
the effects of amphetamine, ketamine and PCP are lost in mGlu2/3 knockout mice {{888 Fell,M.J. 
2009;}}. It is possible that mGlu2/3 agonists may have downstream effects reducing D2High 
expression {{887 Seeman,P. 2009;}}. Further studies of LY404039, LY2140023 and related compounds 
are awaited. 
 
Topiramate, an antiepileptic drug with AMPA antagonist properties has been found to be effective as 
an adjunctive therapy in treatment-resistant patients with schizophrenia {{201 Tiihonen,J. 2005;}}, 
and to reduce the effects of MK-801 in rats {{203 Deutsch,S.I. 2002;}}, although it is possible that 
these effects of topiramate may occur through enhancement of GABA transmission, as AMPA 
antagonism only occurs at higher concentrations {{202 Gibbs, J. W.,3rd 2000;}}. 
 
Other Mechanisms 
The antibiotic minocycline has, somewhat unexpectedly, been shown to inhibit the effects of NMDA 
receptor antagonism by MK-801 on rats {{845 Levkovitz,Y. 2007; 846 Zhang,L. 2007;}}, and to reverse 
PCP-induced cognitive deficits {{847 Fujita,Y. 2008;}}. A double-blind randomised controlled trial of 
minocycline as add-on treatment in patients with early phase schizophrenia (within the first 5 years 
of diagnosis) revealed a significant effect on negative and cognitive symptoms {{848 Levkovitz,Y. 
2010;}}. Although the exact mechanism of action for minocycline in schizophrenia has still to be 
ascertained, it is possible that its effect arises through the inhibition of glutamate excitotoxicity 
(mediated via nitric oxide) by  blocking p38 MAP kinase and c-jun N-terminal kinase (mitogen-
activated protein kinases responsive to stress stimuli that regulate cellular functions including 
neurodegeneration, apoptosis, cell differentiation and proliferation) {{850 Wilkins,A. 2004; 849 Pi,R. 
2004;}}. 
 
Cannabidiol (CBD), a constituent of cannabis, may also have a modulatory effect on glutamatergic 
transmission, as it has been shown to inhibit ketamine and MK-801 induced effects in animal models 
{{853 Moreira,F.A. 2005; 877 Long,L.E. 2006;}}, and in humans {{839 Hallak,J.E. 2010;}}. Cannabis 
users with detectable levels of both CBD and delta-9 tetrahydrocannabinol (THC) in hair samples 
reported a lower incidence of schizophrenia-like symptoms than those in whom THC alone was 
detected {{879 Morgan,C.J. 2008;}}. Furthermore, acute intoxication with cannabis containing low 
CBD led to impairments in recall, whereas high CBD cannabis did not induce any cognitive deficits 
{{878 Morgan,C.J. 2010;}}. Cannabidiol has been shown to have the opposite effect to THC on neural 
activation measured using fMRI during an emotional processing task and a verbal memory task {{934 
Bhattacharyya,S 2010; 935 Fusar-Poli,P. 2009;}}, and pre-treatment with cannabidiol significantly 
attenuates the psychotogenic effects of THC {{936 Karniol,I.G. 1974; 934 Bhattacharyya,S 2010;}}. 
Preliminary work suggests that CBD is effective as an antipsychotic in patients with schizophrenia 
{{291 Zuardi,A.W. 2006;}}, although it had no additional beneficial effect in a small open-label study 
of clozapine-resistant patients {{291 Zuardi,A.W. 2006;}}. 
 
The mechanism of action of CBD has not yet been completely elucidated. It has been demonstrated 
that CBD antagonises the inhibitory effect of endocannabinoids and THC on GABA and glutamate 
transmission, mediated via CB1 receptors {{881 Godino Mdel,C. 2007; 882 Neu,A. 2007;}}. Given the 
hypothesised mechanism of ketamine action on GABA and glutamate systems, it is possible that the 
enhancement of GABA-A function is its primary mode of action in reducing ketamine-induced effects 
(figure 6). However, a CB1 antagonist was not found to be effective in patients with schizophrenia 
{{883 Meltzer,H.Y. 2004;}}, and there is growing evidence that some of the beneficial effects of CBD, 
like minocycline, may be mediated via inhibition of p38 MAP kinase {{885 Esposito,G. 2006;884 El-
Remessy,A.B. 2008;}}. 
 
Drugs targeting glutamate in schizophrenia –  drugs in development. 
GlyT1 Inhibitors 
Several pharmaceutical companies have published data on GlyT1 receptor inhibitors (see Table 1). 
Roche reported in a press release that their GlyT1 inhibitor, RG1678,  was successful in treating 
negative symptoms in a phase-2 drug trial, but they have not published any further data on this 
compound at present {{889 Pinard,E. 2010;}}. Johnson and Johnson have reported that the GlyT1 
inhibitor, R231857, improved scopolamine-induced cognitive impairments in healthy volunteers 
{{890 Liem-Moolenaar,M. 2010;}}. Schering-Plough report that they are investigating the effects of 
Org 25935 on negative symptoms, but no data have yet been released to the public domain. One 
concerning potential side effect of glycine transporter inhibitors is respiratory depression –  although 
it is not clear if this affects all compounds in this class {{891 Perry,K.W. 2008;}}. Another issue is that 
the effect of GlyT1 inhibitors appears to occur only within a particular dose range, increasing NMDA 
receptor currents and long-term potentiation (LTP) within this range, but leading to reductions in 
NMDA receptor currents at higher doses {{892 Martina,M. 2004;}}. 
 
Metabotropic glutamatergic receptors - allosteric potentiators 
There has been some interest in developing allosteric potentiators of metabotropic glutamate 
receptors {{893 Johnson,M.P. 2004;}}, and two pharmaceutical companies have published data on 
these compounds (see Table 1). There are several theoretical advantages of allosteric potentiation in 
targeting the glutamatergic system. As endogenous ligand is required for their action, they should 
have a lower propensity to side effects – they may also be less prone to desensitisation which occurs 
with drugs targeting the active site. LY379268 is an allosteric drug potentiating glutamate signalling 
at the mGlu2 receptor currently in development by Lilly. It has been shown to block ketamine 
induced glutamate release, as well as ketamine induced dopamine and histamine release in the 
prefrontal cortex, and norepinephrine release in hippocampus {{894 Fell,M.J. 2010;896 Lorrain,D.S. 
2003;895 Lorrain,D.S. 2003;}}. It has also been shown to inhibit MK-801 induced retrosplenial cortex 
damage when injected into thalamus or cortex {{897 Carter,K. 2004;}}, suggesting that it may be 
neuroprotective in the early stages of psychosis. 
 
3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) is an allosteric potentiator of the mGlu5 
receptor developed by Merck {{898 Lindsley,C.W. 2004;}}. It increases the affinity of glutamate for the 
receptor, leading to an enhancement of NMDA receptor activity (figure 6). It has been shown to 
attenuate amphetamine-induced PPI deficits {{900 Kinney,G.G. 2005;}}, and to reverse MK-801 
induced elevation in pyramidal cell activity {{899 Lecourtier,L. 2007;}}. It has also been shown to be 
effective  in an animal model of negative symptoms (MK-801 induced impairment of sucrose-
preference) {{902 Vardigan,J.D. 2010;}}, and has shown superior efficacy compared to mglu2/3 
agonists in reversing MK-801 induced cognitive impairment {{903 Vales,K. 2010; 904 Stefani,M.R. 
2010;}}. It shows a U-shaped dose-response curve on cognitive function and on GluR1 
phosphorylation, however, suggesting a fairly tight therapeutic window {{901 Uslaner,J.M. 2009;}}. 
 
Glutamate and illness progression in schizophrenia – a critical window of opportunity? 
 
Elavated cortical glutamate activity in schizophrenia appears to be most marked in the early phases 
of the illness {{643 Théberge,Jean 2002;}} and in the prodrome {{660 Stone,J.M. 2009;}}. Thus, it 
makes intuitive sense that drugs targeting excess glutamate release may be of most benefit when 
given during these stages. Indeed, as the illness progresses, it appears that, rather than being 
overactive, that cortical glutamate  system may be reduced in function compared to healthy 
volunteers {{642 Théberge,Jean 2003;}}. It is tempting to speculate that administration of drugs that 
reduce cortical glutamate release (such as mGlu2/3 agonists), or inhibit its effects (such as AMPA 
antagonists and possibly minocycline) may be disease-modifying if given early enough - preventing 
transition to psychosis in individuals with prodromal symptoms and improving outcome in individuals 
with first-episode schizophrenia. 
 
The evidence for a phase-specific deficit in NMDA receptor function is less clear, however. In one 
small SPECT study with the NMDA receptor ligand [123I]CNS-1261, unmedicated individuals with 
chronic schizophrenia were shown to have reduced NMDA receptor binding in left hippocampus 
{{188 Pilowsky}}. Thus, drugs targeting NMDA receptor enhancement (glycineB agonists, GlyT1 
antagonists and mGlu5 receptor agonists) may be of benefit at other phases of the illness including 
the prodrome and first-episode. 
 
Clearly further work is required to investigate these hypotheses as studies to date have generally 
targeted individuals with chronic schizophrenia. 
 
Conclusions 
Novel drugs targeting glutamate transmission have shown considerable promise in the treatment of 
schizophrenia. Current evidence supports their use as adjunctive agents in individuals who fail to 
respond to conventional dopaminergic antipsychotic drugs, and preliminary data suggests that they 
are also efficacious as monotherapy. There are currently a large number of glutamatergic compounds 
in development, with a great deal of excitement about their potential as novel therapeutic agents in 
schizophrenia. It seems likely that the next wave of drugs for schizophrenia will target this system. 
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Figure 1: 
Glutamatergic synapse showing glutamate release, binding to AMPA and NMDA  receptors on the 
postsynaptic membrane, and subsequent reuptake by astrocytes where it is metabolised to 
glutamine by glutamine synthetase (GS). 
 
  
Figure 2: 
Simplified diagram of an NMDA receptor with glycine (Gly), glutamate (Glu) and MK-
801/PCP/ketamine (PCP) binding sites displayed. Extracellular calcium entry through the NMDA 
receptor occurs only when both glutamate and glycine bind to their respective binding sites, and the 
cell membrane depolarises allowing removal of the voltage-dependent block due to extracellular 
magnesium ions binding inside the pore of the NMDA receptor. 
 
 
  
Figure 3: 
Hypothesised mechanism whereby NMDA receptor antagonists lead to increased cortical glutamate 
release – inhibition of NMDA receptors expressed on GABAergic interneurons (A) leads disinhibition 
of glutamatergic projection neurons (B). 
 
 
  
Figure 4: 
Reduced NMDA receptor binding in left hippocampus in drug free patients with schizophrenia (DF) 
and matched healthy controls (HC) (see Pilowsky et al. 2006). 
 
 
  
Figure 5: 
Reduced NMDA receptor (NMDAR) expression on hippocampal GABA interneurons leads to 
increased sensitivity to reductions in presynaptic glutamate levels and disinhibition of glutamate 
efferents from hippocampus(A) leading to enhanced stimulation of GABA neurons projecting from 
nucleus accumbens (NAcc) to ventral pallidum (VP) resulting in enhanced inhibition of GABA neurons 
projecting from VP to ventral tegmental area (VTA) and disinhibition of dopamine (DA) neurons 
projecting to striatum (after Lodge et al. 2006). 
  
Figure 6: 
Potential targets for drugs to reduce excess cortical glutamate release: Enhancement of NMDA 
receptor function by direct action at glycineB site (2), or by increasing synaptic glycine concentrations 
through block of glycine transporters (1). Enhancement of NMDA receptor function through agonism 
of mGluR5 metabotropic glutamate receptors (3). Enhancement of GABA  interneuron function 
through M1 or nicotinic alpha-7 agonism (4), or enhancement of BDNF function (5).  Enhancement of 
GABA action on alpha-2 containing GABA-A receptors (6). Reduction of the effects of cortical 
glutamate release by blocking AMPA receptors (7), or by reducing glutamate release through 
mGlu2/3 autoreceptor agonism (8). 
 
 
Table 1: 
Glutamatergic drugs currently in development for the treatment of schizophrenia. 
Company name Drug name Mechanism Phase Results 
Roche RG1678 GlyT1 inhibitor Phase II Effective vs. 
negative 
symptoms in 
patients with 
schizophrenia 
Johnson & Johnson R231857 GlyT1 inhibitor Phase I Improved 
scopolamine-
induced cognitive 
impairments in 
healthy volunteers 
Schering-Plough Org 25935 GlyT1 inhibitor ?Phase II No results in 
public domain 
Lilly LY379268 Allosteric mGlu2 
potentiator 
? Preclinical 
effectiveness vs. 
ketamine and MK-
801 models 
Merck CDPPB Allosteric mGlu5 
potentiator 
? Preclinical 
effectiveness vs. 
amphetamine, 
MK-801 and 
sucrose-
preference 
(negative 
symptoms) models 
 
